Intranasal infusion of nanostructured lipid carriers (NLC) containing CNS acting drug and estimation in brain and blood

Drug Delivery

Volumn 20, Issue 6, 2013, Pages 247-251

  Alam, M Intakhab ^a   Baboota, Sanjula ^a   Ahuja, Alka ^b   Ali, Mushir ^a   Ali, Javed ^a   Sahni, Jasjeet K ^a  

^a HAMDARD UNIVERSITY   (India)

^b OMAN MEDICAL COLLEGE   (Oman)

Author keywords

DLX NLC; ex vivo studies; in vivo studies; Lipid nanocarriers; Nasal permeation

Indexed keywords

DULOXETINE; NANOCARRIER;

ANIMAL EXPERIMENT; ARTICLE; CONTINUOUS INFUSION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; DRUG PENETRATION; IN VIVO STUDY; NONHUMAN; NOSE CAVITY; NOSE MUCOSA; PRIORITY JOURNAL; RAT;

ABSORPTION; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; FEMALE; LIPIDS; MALE; NANOSTRUCTURES; NASAL MUCOSA; RATS; RATS, WISTAR; THIOPHENES;

EID: 84880520704     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2013.822945     Document Type: Article

References (25)

1. Alam MI, Baboota S, Ahuja A, et al. (2011). Nanostructured Lipid Carrier Containing CNS Acting Drug: Formulation, Optimization and Evaluation. Cur Nanosci 7:1014-27.
2. Alam MI, Baboota S, Ahuja A, et al. (2012). Intranasal administration of nanostructured lipid carriers containing CNS acting drug: pharmacodynamic studies and estimation in blood and brain. J Psychiatr Res 46: 1133-8.
3. Alam MI, Beg S, Samad A, et al. (2010). Strategy for effective brain drug delivery. Eur J Pharm Sci 40:385-403.
4. Al-Ghananeem AM, Malkawi AH, Crooks PA. (2011). Bioavailability of D9-tetrahydrocannabinol following intranasal administration of a mucoadhesive gel spraydelivery system in conscious rabbits. Drug Dev Ind Pharm 37:329-34.
5. Aungst BJ, Rogers NJ. (1988). Site dependence of absorption-promoting actions of laureth-9, Na salicylate, Na2EDTA, and aprotinin on rectal, nasal, and buccal insulin delivery. Pharm Res 5:305-8.
6. Bjerre C, Bjork E, Camber O. (1996). Bioavailability of the sedative propiomazine after nasal administration in rats. Int J Pharm 144: 217-24.
7. Chen X, Lu Y, Du S, et al. (2010). In Situ and in vivo study of nasal absorption of Paeonol in rats. Int J Mol Sci 11:4882-90.
8. Chien YW. (1985). Transnasal systemic medications: fundamentals, developmental concepts, and biomedical assessments. Amsterdam, New York: Elsevier.
9. Chung FY, Donovan MD. (1996). Nasal pre-systemic metabolism of peptide drugs: substance P metabolism in the sheep nasal cavity. Int J Pharm 128:229-37.
10. Haque S, Shadab M, Alam MI, et al. (2011). Nanomedicines for Brain Targeting: a patent review. Recent Patent Nanomed 1:149-61.
11. Hirai S, Yashika T, Matsuzawa T, Mima H. (1981). Absorption of drugs from the nasal mucosa of rat. Int J Pharm 7:317-25.
12. Huang C, Kimura R, Nassar A, Hussain A. (1985). Mechanism of nasal drug absorption of drug II: absorption of L-Tyrosine and the effect of structural modification on its absorption. J Pharm Res 74:1298-301.
13. Hussain AA. (1998). Intranasal drug delivery. Adv Drug Deliv Rev 29: 39-49.
14. Hussain MA, Aungst BJ. (1994). Nasal mucosal metabolism of an LHRH fragment and inhibition with boroleucine. Int J Pharm 105:7-10.
15. Illum L. (2000). Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 11:1-18.
16. Jabbal-Gill I. (2010). Nasal vaccine innovation. J Drug Targeting 18: 771-86.
17. Kao HD, Traboulsi A, Itoh S, et al. (2000). Enhancement of the systemic and CNS specific delivery of L-dopa by the nasal administration of its water soluble prodrugs. Pharm Res 17:978-84.
18. Maggio ET. (2011). Intranasal administration of active agents to the central nervous system. US Patent 20110129462A1.
19. Mistry A, Stolnik S, Illum L. (2009). Nanoparticles for direct noseto-brain delivery of drugs. Int J Pharm 379:146-57.
20. Nagai T, Nishimoto Y, Nambu N, et al. (1984). Powder dosage form of insulin for nasal administration. J Control Rel 1:15-22.
21. Pires A, Fortuna A, Alves G, Falcao A. (2009). Intranasal Drug Delivery: How, Why and What for?. J Pharm Pharm Sci 12:288-311.
22. Preda M, Leucuta SE. (2003). Oxprenolol-loaded bioadhesive microspheres: preparation and in vitro/in vivo characterization. J Microencapsul 20:777-89.
23. Sakane T, Akizuki M, Yamashita S, et al. (1991). The transport of a drug to the cerebrospinal fluid directly from the nasal cavity: the relation to the lipophilicity of the drug. Chem Pharm Bull 39: 2456-8.
24. Tas C, Ozkan CK, Savaser A, et al. (2006). Nasal absorption of metoclopramide from different Carbopol-981 based formulations: in vitro, ex vivo and in vivo evaluation. Eur J Pharm Biopharm 64: 246-54.
25. Ugwoke MI, Kaufmann G, Verbeke N, Kinget R. (2000). Intranasal bioavailability of apomorphine from carboxymethylcellulose-based drug delivery systems. Int J Pharm 202:125-31.